Very nice to see cohort 2 is now wrapped up, with no dose limiting toxicities... that's actually really good news because there was always a chance the dual administration could lead to complications... though it has been done before, never with CLTX CAR-T. Another big box ticked... and now cohort 3 is recruiting, and will accelerated early 2022 once the two new trial sites open up... data will then be generated at 3 sites, vs 1.. so what took 6 months, can now be done in 2!
and if they wait unti first week of June for the ASCO conference... that's near 6 months follow up for all patients in the second cohort... 75% disease control at the lowest dose... what is cohort 2 going to bring ,with double that low dose and dual administration....
goodluck all!
CHM Price at posting:
25.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)